MBIO
Mustang Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Stock Price Surged Significantly
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MBIO
Mustang Bio, Inc.
A clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases
Biological Technology
03/13/2015
08/22/2017
NASDAQ Stock Exchange
6
12-31
Common stock
95 Sawyer Road, Suite 110, Waltham, MA 02453
--
Mustang Bio, Inc., was incorporated in Delaware on March 13, 2015. The company is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematological cancers, solid tumors and rare genetic diseases. The company's goal is to acquire the rights to these technologies by licensing or otherwise acquiring an ownership interest in these technologies, fund its research and development, and ultimately either outsource the licenses or bring the technologies to market.
Company Financials
EPS
MBIO has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected 0, missing expectations. The chart below visualizes how MBIO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
